Table 1. Point assignments for CPS+EG, Neo-Bioscore, and CPS+EGHlow staging systems.
| Cancer stage | CPS+EG | CPS+EGHlow | Neo-Bioscore |
| ER, estrogen receptor; HER2, human epidermal growth factor receptor 2. | |||
| Clinical stage | |||
| I | 0 | 0 | 0 |
| IIA | 0 | 0 | 0 |
| IIB | 1 | 1 | 1 |
| IIIA | 1 | 1 | 1 |
| IIIB | 2 | 2 | 2 |
| IIIC | 2 | 2 | 2 |
| Pathologic stage | |||
| 0 | 0 | 0 | 0 |
| I | 0 | 0 | 0 |
| IIA | 1 | 1 | 1 |
| IIB | 1 | 1 | 1 |
| IIIA | 1 | 1 | 1 |
| IIIB | 1 | 1 | 1 |
| IIIC | 2 | 2 | 2 |
| Tumor marker | |||
| ER-negative | 1 | 1 | 1 |
| Grade 3 | 1 | 1 | 1 |
| HER2-zero | − | 2 | 1 |
| HER2-low | − | 1 | 1 |
| HER2-amplified | − | 0 | 0 |